Does Transanal Total Mesorectal Excision (taTME) Result in Better Quality of Life and Functional Outcomes Than Traditional Total Mesorectal Excision? A Retrospective Propensity Score-adjusted Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rectal Cancer
- Sponsor
- Cantonal Hospital of St. Gallen
- Enrollment
- 249
- Locations
- 1
- Primary Endpoint
- Quality of life (QoL)
- Status
- Completed
- Last Updated
- 9 months ago
Overview
Brief Summary
The improvement in prognosis of rectal cancer through modern therapy modalities rises questions regarding quality of life (QoL) and functional outcomes. Evidence for long-term QoL and functional outcomes of transanal total mesorectal excision (taTME) is not provided in current literature. This study will compare short-term and long-term QoL and functional outcomes after taTME compared to traditional abdominal TME (laparoscopic, robotic, and open approach)
Detailed Description
Quality of life and functional outcomes of patients undergoing taTME or abTME for stage I-III rectal cancer will be analysed. A retrospective propensity score-adjusted analysis of prospectively conducted data will be performed. The primary endpoint QoL will be assessed by the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30). Secondary endpoints are the functional outcomes according to the EORTC QLQ-C30 questionnaire.
Investigators
Yanic Ammann
Dr. med.
Cantonal Hospital of St. Gallen
Eligibility Criteria
Inclusion Criteria
- •elective total mesorectal excision followed by reconstruction with anastomosis for primary rectal cancer
Exclusion Criteria
- •diagnoses other than rectal cancer
- •recurrent rectal cancer
- •partial mesorectal excision
- •discontinuity resection (no anastomosis)
- •incomplete TNM staging information
- •metastatic cancer
- •30-day mortality
- •lack of quality of life data
- •patient decline
- •age under 18 years
Outcomes
Primary Outcomes
Quality of life (QoL)
Time Frame: 5 years after initial operation
Assessed by the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30): * Overall QoL * QLQ-total
Secondary Outcomes
- Functional outcomes(5 years after initial operation)